Blood Preparation Market

Market Definition

The global Blood Preparation Market size was valued at USD 46.88 billion in 2022 and is predicted to reach USD 72.94 billion by 2030 with a CAGR of 5.69% from 2023 to 2030. Blood preparation refers to the process of collecting, testing, processing, and storing blood and blood components for transfusion or therapeutic use. This involves screening for infectious diseases, separating whole blood into its various components such as red blood cells, plasma, and platelets, and ensuring that these components are properly stored and transported. Blood preparation plays a critical role in ensuring the safety and efficacy of blood transfusions and other blood-based therapies.

Market Dynamics and Trends

The presence of advanced technologies such as centrifugal force to separate components of blood propel the blood preparation market growth. In addition, the launch of various blood-derived medicines such as plasma-based products including Albumin and Intravenous Immunoglobulin (IVIg) for treating patients with immune deficiency disorders propels the market growth.

Moreover, the growing usage of plasma as life-saving therapeutics for several chronic and acute life-threatening diseases such as Hereditary Angioedema and Hemophilia in the pharmaceutical industry is expected to support the growth of the blood preparation market.

However, high chances of transmission of diseases during blood transfusions such as viral hemorrhagic fever, HIV, and hepatitis B restrain the market. In addition, the rise in incidences of allergic reactions at the time of blood transfusion such as hypotensive transfusion reactions are expected to restrain the growth of the market during the forecast period.

On the contrary, innovative blood collection and processing technologies, such as automated blood collection systems, can help reduce processing time and improve quality of blood products, which is expected to create ample growth opportunities for the blood preparation market, in the coming years.

Market Segmentation and Scope of the Study

The global blood preparation market share is segmented on the basis of product, antithrombotic & anticoagulants type, application, end user, and region. On the basis of product, the market is categorized into whole blood, blood components, and blood derivatives.

By whole blood, the market is sub-segmented into granulocytes, red cells, platelets, and plasma. By blood components, it is subdivided into whole blood components, packed red cells, leukocyte-reduced red blood cells, frozen plasma, platelet concentrate, and cryoprecipitate.

On the basis of antithrombotic and anticoagulant types, the market is divided into anticoagulants, platelet aggregation, and fibrinolytic.  Further, on the basis of anticoagulants, the market is classified into heparins. The heparin segment is divided into low molecular weight heparin (LMWH), ultra-low molecular weight heparin, direct thrombin inhibitors, unfractionated heparin, vitamin k antagonists, and direct factor Xa inhibitors.

On the basis of platelet aggregation, the market is sub-divided into glycoprotein inhibitors, cox inhibitors, ADP antagonists, and others. On the basis of fibrinolytics, the market is categorized into tissue plasminogen activator (tPA), streptokinase, and urokinase.

By application, the market is divided into thrombocytosis, pulmonary embolism, renal impairment, angina blood vessel complications, and others. On the basis of end user, it is classified into hospitals, clinics, diagnostic centers, research labs, blood banks, pharmaceuticals, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and Row.

Geographical Analysis

North America holds a predominant share of the blood preparation market and is expected to remain dominant during the forecast period. This is attributed to factors such as presence of a large number of hospitals with advanced technology that execute high surgical procedures, along with growth in cases of leukemia, lymphoma, and hematological. For instance, according to the Leukemia Lymphoma Society (LLS), cases of leukemia, lymphoma, and myeloma accounted for 9.8% of the 1,898,160 cancer cases that were diagnosed in the US in 2021.

In addition, high healthcare expenditure, along with the rise in the prevalence of blood cancer in this region is expected to boost the market growth. For instance, according to Globocan, estimated incidences of cancer cases in the U.S. accounted for 2,281,658, with 612,390 deaths in 2020.

On the other hand, Asia-Pacific is expected to show a steady rise in the market, owing to the rising geriatric population. The aging population is prone to various health conditions that require blood transfusions, such as cancer, cardiovascular diseases, and organ transplants. As the elderly population continues to grow, the demand for blood products and, consequently, blood preparation methods is expected to increase which in turn boost the growth of the blood preparation market.

According to the National Library of Medicine, the proportion of individuals aged 60 years and above in China is projected to rise from 12.4% (168 million) to 28% (402 million) by 2040. This demographic shift is accompanied by a notable burden of chronic non-communicable diseases (NCDs), with approximately 80% of deaths among people aged 60 years and above attributed to chronic NCDs. Thus, proving growth opportunities for the blood preparation market.

Competitive Landscape

The blood preparation industry comprises various market players such as GlaxoSmithKline plc., Baxter Healthcare Corp., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi Aventis, AstraZeneca plc., Celgene Corporation., Leo Pharma A/S, Shandong East Chemical Industry Co., and Daiichi Sankyo. These market players are adopting various strategies such as acquisitions across various regions to maintain their dominance in the blood preparation industry.

For instance, in October 2022, Pfizer completed its acquisition of Global Blood Therapeutics (GBT), a biopharmaceutical company dedicated to discovering, developing, and delivering life-changing treatments for people living with blood disorders. The acquisition is part of Pfizer's ongoing efforts to expand its portfolio of innovative therapies to increase its presence in the rare disease market.

Moreover, in July 2022, GlaxoSmithKline announced acquisition of Sierra Oncology, Inc., a California-based biopharmaceutical company focused on targeted therapies for treatment of rare forms of cancer. This acquisition includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address critical unmet medical needs of myelofibrosis patients with anemia.

Key Benefits

• The report provides quantitative analysis and estimations of the blood preparation industry from 2022 to 2030, which assists in identifying the prevailing market opportunities.

• The study comprises a deep dive analysis of the blood preparation market including the current and future trends to depict prevalent investment pockets in the market.

• Information related to key drivers, restraints, and opportunities and their impact on the market is provided in the report. 

• Competitive analysis of the players, along with their share in the blood preparation marker, is provided in the report.

• SWOT analysis and Porter's Five Forces model is elaborated in the study.

• Value chain analysis in the market study provides a clear picture of the roles of stakeholders.

Blood Preparation Market Key Segments

By Product

• Whole Blood

  • Granulocytes

  • Red Cells

  • Platelets

  • Plasma

• Blood Components

  • Whole Blood Components

  • Packed Red Cells

  • Leukocyte Reduced Red Blood Cells

  • Frozen Plasma

  • Platelet Concentrate 

  • Cryoprecipitate

• Blood Derivatives

By Antithrombotic and Anticoagulants Type

• Anticoagulants

  • Hepparins

    • Low Molecular Weight Heparin (Lmwh)

    • Ultra-Low Molecular Weight Heparin

    • Direct Thrombin Inhibitors

    • Unfractionated Heparin

  • Vitamin K Antagonists 

    • Direct Factor Xa Inhibitors

• Platelet Aggregation 

  • Glycoprotein Inhibitors

  • Cox Inhibitors

  • Adp Antagonists

  • Others

• Fibrinolytics 

  • Tissue Plasminogen Activator (TPA)

  • Streptokinase 

  • Urokinase

By Application

• Thrombocytosis

• Pulmonary Embolism

• Renal Impairment

• Angina Blood Vessel Complications 

• Others

By End User 

• Hospitals

• Clinics

• Diagnostic centers

• Research Labs

• Blood banks

• Pharmaceuticals

• Others

By Region

• North America

  • U.S.

  • Canada    

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy 

  • Spain

  • Denmark

  • Netherlands

  • Finland

  • Sweden    

  • Norway    

  • Russia

  • Rest of Europe

• Asia Pacific

  • China 

  • Japan 

  • India

  • South Korea

  • Australia

  • Indonesia

  • Singapore

  • Taiwan

  • Thailand 

  • Rest of Asia-Pacific

• Rest of World

  • Latin America

  • Middle East

  • Africa

KEY PLAYERS

• GlaxoSmithKline plc

• Baxter Healthcare Corp.

• Pfizer Inc.

• Bristol-Myers Squibb Company

• Sanofi Aventis

• AstraZeneca plc.

• Celgene Corporation.

• Leo Pharma A/S.

• Shandong East Chemical Industry Co.

• Daiichi Sankyo